UNICA IRIS Institutional Research Information System

CAOCCI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 497.298
NA - Nord America 18.455
AS - Asia 9.563
SA - Sud America 1.638
AF - Africa 241
OC - Oceania 63
Continente sconosciuto - Info sul continente non disponibili 11
Totale 527.269
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 487.030
US - Stati Uniti d'America 18.138
NL - Olanda 5.123
SG - Singapore 3.723
CN - Cina 3.025
BR - Brasile 1.265
SE - Svezia 1.253
UA - Ucraina 1.158
VN - Vietnam 995
FI - Finlandia 699
GB - Regno Unito 516
DE - Germania 510
FR - Francia 502
HK - Hong Kong 366
IN - India 332
KR - Corea 218
CA - Canada 180
AR - Argentina 136
BD - Bangladesh 111
IQ - Iraq 111
AT - Austria 92
MX - Messico 92
JP - Giappone 87
TR - Turchia 78
ZA - Sudafrica 76
PL - Polonia 74
RU - Federazione Russa 72
EC - Ecuador 65
PK - Pakistan 63
AU - Australia 54
IR - Iran 54
ID - Indonesia 49
SA - Arabia Saudita 46
VE - Venezuela 45
IE - Irlanda 44
MY - Malesia 39
ES - Italia 38
MA - Marocco 37
BE - Belgio 32
CO - Colombia 32
PH - Filippine 32
UZ - Uzbekistan 27
AE - Emirati Arabi Uniti 26
CL - Cile 25
EG - Egitto 24
JO - Giordania 23
TH - Thailandia 22
CZ - Repubblica Ceca 21
PY - Paraguay 21
KE - Kenya 19
LT - Lituania 19
TN - Tunisia 19
PE - Perù 18
IL - Israele 17
UY - Uruguay 17
CH - Svizzera 15
DZ - Algeria 15
RO - Romania 15
AZ - Azerbaigian 14
ET - Etiopia 13
KZ - Kazakistan 13
OM - Oman 13
BO - Bolivia 12
NP - Nepal 12
BG - Bulgaria 11
DK - Danimarca 11
EU - Europa 11
LB - Libano 10
TW - Taiwan 10
JM - Giamaica 9
PS - Palestinian Territory 9
BY - Bielorussia 8
NZ - Nuova Zelanda 8
PT - Portogallo 8
GE - Georgia 7
HU - Ungheria 7
PA - Panama 7
DO - Repubblica Dominicana 6
GR - Grecia 6
SY - Repubblica araba siriana 6
KG - Kirghizistan 5
PR - Porto Rico 5
AL - Albania 4
AM - Armenia 4
CI - Costa d'Avorio 4
CR - Costa Rica 4
HR - Croazia 4
LV - Lettonia 4
MU - Mauritius 4
NG - Nigeria 4
QA - Qatar 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
TT - Trinidad e Tobago 4
BW - Botswana 3
CG - Congo 3
HN - Honduras 3
LY - Libia 3
MD - Moldavia 3
NI - Nicaragua 3
Totale 527.222
Salva come PNG Salva come JPEG
Città #
Cagliari 459.014
Uta 26.252
Amsterdam 5.042
Singapore 1.796
Fairfield 1.726
Ashburn 1.684
Woodbridge 1.326
Dallas 1.050
San Jose 966
Boardman 955
Houston 876
Chandler 844
Nyköping 709
Wilmington 708
Seattle 703
Ann Arbor 689
Cambridge 618
Jacksonville 592
Beijing 575
Helsinki 474
Los Angeles 426
New York 408
Hong Kong 324
Ho Chi Minh City 298
Lauterbourg 273
Hefei 269
Council Bluffs 261
Nanjing 217
Boston 214
Santa Clara 202
Seoul 199
Hanoi 177
Dong Ket 170
Shanghai 165
Milan 159
The Dalles 156
Buffalo 147
Rome 146
Dearborn 125
San Diego 118
São Paulo 117
Guangzhou 94
Redondo Beach 84
Orem 83
Chicago 81
Atlanta 74
Munich 71
Toronto 70
London 68
Redwood City 67
Shenyang 67
Tokyo 62
Nanchang 61
Tianjin 61
Hebei 59
Chennai 58
Frankfurt am Main 58
Menlo Park 57
Nuremberg 57
Rio de Janeiro 57
Changsha 56
Mountain View 56
Phoenix 54
Warsaw 54
Norwalk 45
Vienna 43
Baghdad 42
Denver 42
Brooklyn 41
Da Nang 41
Johannesburg 41
Haiphong 39
Jiaxing 39
Washington 39
Manchester 36
Pune 35
Verona 35
Montreal 33
Orange 33
Jinan 32
Sassari 32
Falls Church 29
Mumbai 29
Brussels 28
Lappeenranta 28
Wuhan 28
San Francisco 27
Zhengzhou 27
Hangzhou 26
Paris 26
Tashkent 26
Shenzhen 25
New Delhi 24
Stockholm 24
Düsseldorf 23
Poplar 22
Dublin 21
Naples 21
Sydney 21
Auburn Hills 20
Totale 513.802
Salva come PNG Salva come JPEG
Nome #
Patient-Physician Communication in Acute Myeloid Leukemia and Myelodysplastic Syndrome 242.315
Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis 4.563
HLA-G expression and role in advanced-stage classical Hodgkin lymphoma 3.584
Leucocyte classification for leukaemia detection using image processing techniques 3.574
Comparison Between an Artificial Neural Network and Logistic Regression in Predicting Long Term Kidney Transplantation Outcome 3.427
Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors 3.396
Absence of activating killer immunoglobulin-like receptor genes combined with hepatitis C viral genotype is predictive of hepatocellular carcinoma 3.363
Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients 3.342
What unrelated hematopoietic stem cell transplantation in thalassemia taught us about transplant immunogenetics 3.317
Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients 3.306
HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia 3.231
Reassessing the approach to informed consent: The case of unrelated hematopoietic stem cell transplantation in adult thalassemia patients 3.043
Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A "Campus CML" Study 2.915
KIR and their HLA Class I ligands: Two more pieces towards completing the puzzle of chronic rejection and graft loss in kidney transplantation 2.910
Kir haplotype aa is a possible predictive marker of complete molecular response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia 2.825
Ruolo del trapianto allogenico nelle talassemie 2.767
The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma 2.745
Absence of histological myopathy in chronic myeloid leukemia patients complaining of muscle spasms and myalgia during treatment with nilotinib 2.716
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 2.606
Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients 2.602
A genome-wide association study by ImmunoChip reveals potential modifiers in myelodysplastic syndromes 2.520
Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia 2.250
Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors 2.241
Health related quality of life in patients with onco-hematological diseases 2.233
Favourable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib 2.190
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 2.119
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention 2.115
Role of human leukocyte antigen-G 14-base pair polymorphism in kidney transplantation outcomes 2.108
Homozygosity for Killer Immunoglobin-like Receptor (KIR) Haplotype a Is Associated to Negative Interim Positron Emission Tomography (PET) and a Favourable Outcome in Hodgkin Lymphoma 2.054
Ethical issues of unrelated hematopoietic stem cell transplantation in adult thalassemia patients 1.982
Recipient CTLA-4*CT60-AA genotype is a prognostic factor for acute graft-versus-host disease in hematopoietic stem cell transplantation for thalassemia 1.959
Ruxolitinib therapy and telomere length in myelofibrosis 1.954
Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life 1.936
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice 1.874
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors 1.833
Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis 1.831
THE HLA-G 14-BP POLYMORPHISM IS AN INDEPENDENT GENETIC RISK MARKER OF LONG-TERM KIDNEY TRANSPLANTATION OUTCOME 1.806
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 1.802
null 1.759
The human leukocyte antigen-g 14-bp polymorphism is an independent genetic risk marker of long-term kidney transplantation outcome 1.754
Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review 1.743
Increased incidence of infection in patients with myelofibrosis and transfusion-associated iron overload in the clinical setting 1.674
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors 1.609
Acute basophilic leukemia with U2AF1 mutation 1.592
Defibrotide in the COVID-19 coagulopathy: what is the timing? 1.580
Systemic Mastocytosis with Associated Primary Myelofibrosis 1.568
Thresholds for clinical importance were defined for the EORTC CAT Core - an adaptive measure of core quality of life domains in oncology clinical practice and research 1.564
Unrelated bone marrow transplantation in Thalassemia. The experience of the Italian Bone Marrow transplant Group (GITMO) 1.551
T cell tyrosine phosphorylation response to transient redox stress 1.548
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 1.533
Erythroblast morphology in refractory anemia with ring sideroblasts and thrombocytosis 1.527
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib 1.527
Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research 1.510
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study 1.495
Multifactorial pathogenesis of COVID-19-related coagulopathy. Can defibrotide have a role in the early phases of coagulation disorders? 1.483
Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report 1.464
Successful and safe stem cell mobilization using plerixafor in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia 1.463
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency 1.455
Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation 1.445
Perls stain grade in bone marrow aspirate correlates with overall survival in low-risk myelodysplastic patients 1.442
Return to normal life after hematopoietic stem cell transplantation for thalassemia: a study of patients transplanted from matched sibling donors 1.438
null 1.419
Resolution of capillary leak syndrome by extracorporeal membrane oxygenation 1.401
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients 1.398
The usefulness of artificial neural networks in predicting the outcome of hematopoietic stem cell transplantation 1.365
Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy 1.342
Systemic mastocytosis with associated BCRABL1-negative atypical chronic myeloid leukemia 1.335
Interactions between killer immunoglobulin-like receptors and their human leucocyte antigen Class I ligands influence the outcome of unrelated haematopoietic stem cell transplantation for thalassaemia: a novel predictive algorithm 1.330
A simulated case of chronic myeloid leukemia: the growing risk of Munchausen’s Syndrome by internet 1.318
Immunological deregulation in classic hodgkin lymphoma 1.313
Rectal involvement in pre-early T acute lymphoblastic leukemia 1.302
Comparison between an artificial neural network and logistic regression in predicting acute graft-versus-host disease following unrelated donor hematopoietic stem cell transplantation in thalassemia patients 1.301
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 1.294
Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major 1.277
Cytomegalovirus reactivation in patients under immunosuppressive treatment for autoimmune haemolytic anaemia 1.229
Kikuchi-Fujimoto disease associated with hemophagocytic lymphohistiocytosis following the BNT162b2 mRNA COVID-19 vaccination 1.217
The role of inhibitory KIR 2DL5 in the outcome of autologous hematopoietic stem cell transplantation for multiple myeloma 1.215
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: A multicentre, prospective, observational, cohort study 1.212
White Blood Cell Count Nadir and Duration of Aplasia Do Not Associate with Treatment Outcome in Adult Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy 1.196
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes 1.189
The usefulness of artificial neural networks in predicting the outcome of hematopoietic stem cell transplantation: a crystal ball to foresee the future? 1.165
Evaluating the Thresholds for Clinical Importance of the EORTC QLQ-C15-PAL in Patients Receiving Palliative Treatment 1.147
null 1.138
null 1.128
Comparison between an artificial neural network and logistic regression in predicting acute graft-versus-host disease following unrelated haematopoietic stem cell transplantation 1.124
The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index 1.112
null 1.110
High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity 1.096
Complement-mediated oxidative damage of red cells impairs response to eculizumab in a G6PD-deficient patient with PNH 1.077
Paroxysmal nocturnal hemoglobinuria: clinical expression and response to treatment are modified by a unique interaction with co-existing glucose 6-phosphate dehydrogenase deficiency 1.052
Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)? 1.051
null 1.048
Complement Activation in Paroxysmal Nocturnal Hemoglobinuria (PNH) Causes Oxidative Damage Which May Affect Response to Eculizumab 1.039
Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned? 1.037
Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis 1.035
null 1.034
The association between Major Depressive Disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort study 1.016
Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia on tyrosine kinase inhibitors 1.009
Occurrence of immune thrombocytopenic purpura in a patient with essential thrombocythemia: How the immune system can overcome a neoplastic clone 1.007
Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment 1.000
Totale 421.156
Salva come PNG Salva come JPEG
Categoria #
all - tutte 638.366
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 638.366
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20219.533 0 0 0 0 0 0 0 0 0 4.278 3.109 2.146
2021/202217.322 1.674 1.367 820 915 1.235 1.281 835 875 1.405 2.021 2.587 2.307
2022/202322.185 1.654 2.475 2.451 1.687 2.012 2.372 961 2.724 1.364 1.400 2.052 1.033
2023/202426.605 1.275 1.050 1.468 1.954 2.229 4.706 3.680 1.828 1.345 2.031 2.505 2.534
2024/2025293.370 9.854 102.071 155.748 7.048 3.270 4.843 3.908 332 895 3.804 684 913
2025/202619.425 1.171 924 2.326 1.763 1.268 1.233 4.821 908 3.348 1.663 0 0
Totale 528.340